Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 4/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | EDNRB | P24530 | 2/20 | 0.46 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807015 | 0.89 | SERPINE1 (0.62) | SERPINE1FOLH1EDNRBEDNRAPTGES | |
| SCHEMBL2811879 | 0.88 | SERPINE1 (0.55) | SERPINE1FOLH1EDNRBEDNRAPPARG | |
| SCHEMBL2811200 | 0.88 | SERPINE1 (0.53) | SERPINE1FOLH1EDNRBEDNRAPTGES | |
| SCHEMBL2808907 | 0.85 | SERPINE1 (0.52) | SERPINE1FOLH1EGFREDNRBEDNRA | |
| SCHEMBL2810203 | 0.85 | SERPINE1 (0.62) | SERPINE1FOLH1EDNRBEDNRAPPARG | |
| SCHEMBL13131775 | 0.84 | SERPINE1 (0.51) | SERPINE1FOLH1EDNRBEDNRAPPARG | |
| SCHEMBL2806746 | 0.83 | SERPINE1 (0.46) | SERPINE1EGFRPPARG | |
| SCHEMBL2806705 | 0.83 | SERPINE1 (0.50) | SERPINE1FOLH1EDNRBEDNRAPPARG | |
| SCHEMBL2806758 | 0.82 | SERPINE1 (0.63) | SERPINE1FOLH1EDNRBEDNRAPPARG | |
| SCHEMBL2807174 | 0.82 | SERPINE1 (0.61) | SERPINE1FOLH1EDNRBEDNRAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | claimed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| EP-2081894-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SmithKline Beecham Corporation (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028118-A1 | 1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS PPAR MODULATORS | SMITHKLINE BEECHAM CORPORAITON (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | SERPINE1 4215/4885FOLH1 2056/4885EGFR 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.